<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Inventiva Sa — News on 6ix</title>
<link>https://6ix.com/company/inventiva-sa-1</link>
<description>Latest news and press releases for Inventiva Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/inventiva-sa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d53303beedb30cb6f6de82.webp</url>
<title>Inventiva Sa</title>
<link>https://6ix.com/company/inventiva-sa-1</link>
</image>
<item>
<title>Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-strengthens-leadership-team-ahead-of-expected-phase-3-data-readout-of-lanifibranor-2</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-strengthens-leadership-team-ahead-of-expected-phase-3-data-readout-of-lanifibranor-2</guid>
<pubDate>Wed, 22 Apr 2026 20:00:00 GMT</pubDate>
<description>Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva’s organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes joins as Chief Financial Officer, bringing more than 30 years of investment banking and corporate leadership experience, including recently playing an instrumental role in CureVac’s acquisition by BioNTech.Susan Coles joins as Chief Legal Officer, bringing more than 25 years of experience guiding l</description>
</item>
<item>
<title>Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-filing-of-its-2025-universal-registration-document-and-2025-annual-report-on-form-20-f-1</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-filing-of-its-2025-universal-registration-document-and-2025-annual-report-on-form-20-f-1</guid>
<pubDate>Wed, 08 Apr 2026 20:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that it had filed its 2025 Universal Registration Document for the year ended December 31, 2025, including the management report and the annual financial report, with the French Autori</description>
</item>
<item>
<title>Inventiva reports 2025 full year results and provides a business update</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-reports-2025-full-year-results-and-provides-a-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-reports-2025-full-year-results-and-provides-a-business-update-1</guid>
<pubDate>Mon, 30 Mar 2026 20:11:00 GMT</pubDate>
<description>Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million2)Cash runway expected until the middle of the first quarter of 20273Completed the sale of odiparcil with potential milestone payments of up to $90 million and potential royalties on future net sales, if approvedTopline results of N</description>
</item>
<item>
<title>Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-schedules-the-publication-and-presentation-of-its-2025-full-year-financial-results-2</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-schedules-the-publication-and-presentation-of-its-2025-full-year-financial-results-2</guid>
<pubDate>Mon, 23 Mar 2026 21:00:00 GMT</pubDate>
<description>Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that it will release its 2025 full-year financial results on Monday, March 30, 2026, after market close in the United States. Inventiva’s management will hold a conference call in Eng</description>
</item>
<item>
<title>Inventiva to Participate in Four Upcoming March Investor Conferences</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-to-participate-in-four-upcoming-march-investor-conferences-1</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-to-participate-in-four-upcoming-march-investor-conferences-1</guid>
<pubDate>Thu, 26 Feb 2026 21:14:00 GMT</pubDate>
<description>Daix (France), New York (United States), February 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference</description>
</item>
<item>
<title>Inventiva reports preliminary 2025¹ fiscal year financial results</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-reports-preliminary-2025-fiscal-year-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-reports-preliminary-2025-fiscal-year-financial-results</guid>
<pubDate>Tue, 17 Feb 2026 07:30:00 GMT</pubDate>
<description>Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds of approximately $172.5 million (€149 million3)Cash runway expected until the middle of the first quarter of 20274 Daix (France), New York City (New York, United States), February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceu</description>
</item>
<item>
<title>Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026</guid>
<pubDate>Wed, 04 Feb 2026 21:00:00 GMT</pubDate>
<description>Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February</description>
</item>
<item>
<title>Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux</title>
<link>https://6ix.com/company/inventiva-sa-1/news/half-year-review-of-inventivas-liquidity-contract-with-kepler-cheuvreux</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/half-year-review-of-inventivas-liquidity-contract-with-kepler-cheuvreux</guid>
<pubDate>Mon, 26 Jan 2026 21:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventi</description>
</item>
<item>
<title>Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-to-present-at-the-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Wed, 17 Dec 2025 21:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), December 17, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to present a corporate overview, and will engage with Inventiva’s leadership team in investor meetings, at the upcoming 44</description>
</item>
<item>
<title>Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025</title>
<link>https://6ix.com/company/inventiva-sa-1/news/results-of-the-votes-of-the-combined-shareholders-general-meeting-of-november-27-2025</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/results-of-the-votes-of-the-combined-shareholders-general-meeting-of-november-27-2025</guid>
<pubDate>Fri, 28 Nov 2025 07:30:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Thursday November 27, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Past</description>
</item>
<item>
<title>Information relating to the stabilization activities carried out in the context of its recent offering</title>
<link>https://6ix.com/company/inventiva-sa-1/news/information-relating-to-the-stabilization-activities-carried-out-in-the-context-of-its-recent-offering</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/information-relating-to-the-stabilization-activities-carried-out-in-the-context-of-its-recent-offering</guid>
<pubDate>Mon, 24 Nov 2025 21:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 24, 2025 – Publication of information relating to the stabilization activities carried out in the context of the recent public offering of Inventiva (the "Company" or "Inventiva") in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01. As announced on 18 November 2025, the underwriters have exercised in full their opt</description>
</item>
<item>
<title>Inventiva reports 2025 Third Quarter Financial Information¹</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-reports-2025-third-quarter-financial-information</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-reports-2025-third-quarter-financial-information</guid>
<pubDate>Fri, 21 Nov 2025 21:00:00 GMT</pubDate>
<description>Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the end of the first quarter of 20273, including net proceeds from the November 2025 public offering. Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focuse</description>
</item>
<item>
<title>Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-full-exercise-of-underwriters-option-bringing-proceeds-of-offering-to-approximately-dollar1725m</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-full-exercise-of-underwriters-option-bringing-proceeds-of-offering-to-approximately-dollar1725m</guid>
<pubDate>Mon, 17 Nov 2025 07:30:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the underwriters of the previously announced public offering in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each repre</description>
</item>
<item>
<title>Inventiva announces trading resumption of its ordinary shares on Euronext Paris</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris</guid>
<pubDate>Thu, 13 Nov 2025 15:25:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET). Trading of the ordinary shares of the Company was halte</description>
</item>
<item>
<title>Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-pricing-of-upsized-public-offering-of-approximately-dollar150m-of-american-depositary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-pricing-of-upsized-public-offering-of-approximately-dollar150m-of-american-depositary-shares</guid>
<pubDate>Thu, 13 Nov 2025 14:22:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the pricing of its previously announced underwritten public offering, in the United States only, of 38,961,038 new American Depositary Shares ("ADSs"), each represen</description>
</item>
<item>
<title>Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-paris</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-paris</guid>
<pubDate>Thu, 13 Nov 2025 07:40:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company’s request, from the openi</description>
</item>
<item>
<title>Inventiva announces launch of public offering</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-launch-of-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-launch-of-public-offering</guid>
<pubDate>Wed, 12 Nov 2025 21:25:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that it plans to offer and sell approximatively $125 million (representing approximately €108 million) of new American Depositary Shares ("ADSs") each representing o</description>
</item>
<item>
<title>Combined General Meeting of November 27, 2025 - Availability of the preparatory documents</title>
<link>https://6ix.com/company/inventiva-sa-1/news/combined-general-meeting-of-november-27-2025-availability-of-the-preparatory-documents</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/combined-general-meeting-of-november-27-2025-availability-of-the-preparatory-documents</guid>
<pubDate>Thu, 06 Nov 2025 21:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), November 6, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the availability of the preparatory documents for the Combined General Meeting of November 27, 2025. Shareholders are invited to participate in the Combined General</description>
</item>
<item>
<title>Inventiva Announces the Implementation of a New ATM Program</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-the-implementation-of-a-new-atm-program</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-announces-the-implementation-of-a-new-atm-program</guid>
<pubDate>Tue, 14 Oct 2025 20:00:00 GMT</pubDate>
<description>Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) has filed today a shelf registration statement on Form F-3 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”). The Registration Statement includes a b</description>
</item>
<item>
<title>Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025</title>
<link>https://6ix.com/company/inventiva-sa-1/news/inventiva-to-present-multiple-abstracts-at-aasld-the-liver-meetingr-2025</link>
<guid isPermaLink="true">https://6ix.com/company/inventiva-sa-1/news/inventiva-to-present-multiple-abstracts-at-aasld-the-liver-meetingr-2025</guid>
<pubDate>Tue, 07 Oct 2025 20:00:00 GMT</pubDate>
<description>Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 studyPresentation of digital pathology data from preclinical studies with lanifibranor Daix (France), New York City (New York, United States), October 7, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steat</description>
</item>
</channel>
</rss>